Oppenheimer Asset Management Inc. Sells 2,071 Shares of Balchem Co. (NASDAQ:BCPC)

Oppenheimer Asset Management Inc. lessened its position in Balchem Co. (NASDAQ:BCPC) by 10.1% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 18,511 shares of the basic materials company’s stock after selling 2,071 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Balchem were worth $3,258,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently bought and sold shares of the company. nVerses Capital LLC bought a new stake in shares of Balchem in the third quarter valued at approximately $35,000. Bessemer Group Inc. raised its stake in Balchem by 568.9% during the 1st quarter. Bessemer Group Inc. now owns 301 shares of the basic materials company’s stock valued at $47,000 after purchasing an additional 256 shares during the last quarter. Blue Trust Inc. boosted its holdings in Balchem by 642.5% in the 3rd quarter. Blue Trust Inc. now owns 839 shares of the basic materials company’s stock valued at $148,000 after purchasing an additional 726 shares during the period. GAMMA Investing LLC grew its position in Balchem by 73.4% in the 3rd quarter. GAMMA Investing LLC now owns 841 shares of the basic materials company’s stock worth $148,000 after purchasing an additional 356 shares during the last quarter. Finally, Private Advisor Group LLC bought a new position in shares of Balchem during the 3rd quarter worth about $220,000. Institutional investors own 87.91% of the company’s stock.

Balchem Trading Up 0.5 %

Shares of BCPC stock opened at $177.77 on Friday. The firm has a fifty day moving average of $172.71 and a 200-day moving average of $165.42. The stock has a market cap of $5.78 billion, a price-to-earnings ratio of 47.79, a P/E/G ratio of 5.30 and a beta of 0.65. Balchem Co. has a 52-week low of $120.76 and a 52-week high of $186.03. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.90 and a current ratio of 2.98.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. HC Wainwright lifted their target price on Balchem from $185.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, November 4th. StockNews.com upgraded Balchem from a “hold” rating to a “buy” rating in a research report on Monday, October 28th.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.